JP2018525354A5 - - Google Patents

Download PDF

Info

Publication number
JP2018525354A5
JP2018525354A5 JP2018500605A JP2018500605A JP2018525354A5 JP 2018525354 A5 JP2018525354 A5 JP 2018525354A5 JP 2018500605 A JP2018500605 A JP 2018500605A JP 2018500605 A JP2018500605 A JP 2018500605A JP 2018525354 A5 JP2018525354 A5 JP 2018525354A5
Authority
JP
Japan
Prior art keywords
seq
region
cdr1
cdr2
cdr3 sequences
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2018500605A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018525354A (ja
JP6892431B2 (ja
Filing date
Publication date
Priority claimed from PCT/EP2015/065900 external-priority patent/WO2016005593A1/en
Application filed filed Critical
Priority claimed from PCT/EP2016/066353 external-priority patent/WO2017009258A1/en
Publication of JP2018525354A publication Critical patent/JP2018525354A/ja
Publication of JP2018525354A5 publication Critical patent/JP2018525354A5/ja
Priority to JP2021088877A priority Critical patent/JP7428680B2/ja
Application granted granted Critical
Publication of JP6892431B2 publication Critical patent/JP6892431B2/ja
Priority to JP2024009200A priority patent/JP2024038480A/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2018500605A 2015-07-10 2016-07-08 癌治療用のaxl特異的抗体−薬物コンジュゲート Expired - Fee Related JP6892431B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2021088877A JP7428680B2 (ja) 2015-07-10 2021-05-27 癌治療用のaxl特異的抗体-薬物コンジュゲート
JP2024009200A JP2024038480A (ja) 2015-07-10 2024-01-25 癌治療用のaxl特異的抗体-薬物コンジュゲート

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
PCT/EP2015/065900 WO2016005593A1 (en) 2014-07-11 2015-07-10 Antibodies binding axl
EPPCT/EP2015/065900 2015-07-10
US201662278283P 2016-01-13 2016-01-13
US62/278,283 2016-01-13
PCT/EP2016/066353 WO2017009258A1 (en) 2015-07-10 2016-07-08 Axl-specific antibody-drug conjugates for cancer treatment

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2021088877A Division JP7428680B2 (ja) 2015-07-10 2021-05-27 癌治療用のaxl特異的抗体-薬物コンジュゲート

Publications (3)

Publication Number Publication Date
JP2018525354A JP2018525354A (ja) 2018-09-06
JP2018525354A5 true JP2018525354A5 (enExample) 2019-08-15
JP6892431B2 JP6892431B2 (ja) 2021-06-23

Family

ID=57756861

Family Applications (5)

Application Number Title Priority Date Filing Date
JP2018500605A Expired - Fee Related JP6892431B2 (ja) 2015-07-10 2016-07-08 癌治療用のaxl特異的抗体−薬物コンジュゲート
JP2018536482A Pending JP2019509257A (ja) 2016-01-13 2017-01-13 癌治療用のaxl特異的抗体−薬物コンジュゲート
JP2021088877A Active JP7428680B2 (ja) 2015-07-10 2021-05-27 癌治療用のaxl特異的抗体-薬物コンジュゲート
JP2021207104A Withdrawn JP2022037170A (ja) 2016-01-13 2021-12-21 癌治療用のaxl特異的抗体-薬物コンジュゲート
JP2024009200A Pending JP2024038480A (ja) 2015-07-10 2024-01-25 癌治療用のaxl特異的抗体-薬物コンジュゲート

Family Applications After (4)

Application Number Title Priority Date Filing Date
JP2018536482A Pending JP2019509257A (ja) 2016-01-13 2017-01-13 癌治療用のaxl特異的抗体−薬物コンジュゲート
JP2021088877A Active JP7428680B2 (ja) 2015-07-10 2021-05-27 癌治療用のaxl特異的抗体-薬物コンジュゲート
JP2021207104A Withdrawn JP2022037170A (ja) 2016-01-13 2021-12-21 癌治療用のaxl特異的抗体-薬物コンジュゲート
JP2024009200A Pending JP2024038480A (ja) 2015-07-10 2024-01-25 癌治療用のaxl特異的抗体-薬物コンジュゲート

Country Status (22)

Country Link
US (4) US20180326084A1 (enExample)
EP (3) EP3319993B1 (enExample)
JP (5) JP6892431B2 (enExample)
KR (1) KR20180033523A (enExample)
CN (3) CN108368171A (enExample)
AU (3) AU2016292762B2 (enExample)
CA (2) CA2991805A1 (enExample)
CY (1) CY1123983T1 (enExample)
DK (1) DK3319993T3 (enExample)
EA (2) EA201890272A1 (enExample)
ES (2) ES2784685T3 (enExample)
HR (1) HRP20200551T1 (enExample)
HU (1) HUE049072T2 (enExample)
IL (2) IL256790B (enExample)
LT (1) LT3319993T (enExample)
ME (1) ME03772B (enExample)
PL (1) PL3319993T3 (enExample)
PT (1) PT3319993T (enExample)
RS (1) RS60141B1 (enExample)
SI (1) SI3319993T1 (enExample)
SM (1) SMT202000359T1 (enExample)
WO (2) WO2017009258A1 (enExample)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3169706B1 (en) 2014-07-11 2019-12-04 Genmab A/S Antibodies binding axl
CA2991805A1 (en) * 2015-07-10 2017-01-19 Genmab A/S Axl-specific antibody-drug conjugates for cancer treatment
MX2018008300A (es) 2016-01-13 2018-09-21 Genmab As Formulacion para anticuerpo y conjugado de farmaco del mismo.
AU2017269335B2 (en) 2016-05-26 2021-07-01 Recurium Ip Holdings, Llc EGFR inhibitor compounds
MA45625A (fr) 2016-07-08 2019-05-15 Genmab As Nouveaux régimes posologiques pour conjugués anticorps-médicaments à base d'anticorps anti-axl
EP3515446B1 (en) 2016-09-19 2023-12-20 Novartis AG Therapeutic combinations comprising a raf inhibitor and a erk inhibitor
CN110291089B (zh) 2017-01-17 2022-05-27 海帕瑞吉尼克斯股份有限公司 用于促进肝再生或者减少或预防肝细胞死亡的蛋白激酶抑制剂
US11266653B2 (en) 2017-05-02 2022-03-08 Novartis Ag Combination therapy
AU2018329925B2 (en) 2017-09-08 2025-05-29 F. Hoffmann-La Roche Ag Diagnostic and therapeutic methods for cancer
JP7366886B2 (ja) 2017-09-13 2023-10-23 ナショナル リサーチ カウンシル オブ カナダ Axl特異的抗体及びその使用
EP3773586A1 (en) * 2018-03-30 2021-02-17 Novartis AG A triple pharmaceutical combination comprising dabrafenib, trametinib and an erk inhibitor
EP3774904A1 (en) * 2018-04-10 2021-02-17 Genmab A/S Axl-specific antibodies for cancer treatment
CN110483639A (zh) 2018-05-15 2019-11-22 复旦大学 靶向axl的抗体及抗体-药物偶联物及其制备方法和用途
CN110540592B (zh) * 2018-05-29 2022-08-09 杭州尚健生物技术有限公司 结合axl蛋白的抗体及其应用
US20210393793A1 (en) * 2018-09-26 2021-12-23 Genmab A/S Axl-specific antibodies for treatment of non-small cell lung cancer
AU2020243076A1 (en) 2019-03-20 2021-10-14 Centre National De La Recherche Scientifique - Cnrs - Antibodies having specificity for BTN2 and uses thereof
EP3946453A4 (en) * 2019-03-29 2022-12-07 Celldex Therapeutics, Inc. ANTI-AXL ANTIBODIES AND THEIR METHODS OF USE
ES3025633T3 (en) 2019-05-13 2025-06-09 Novartis Ag New crystalline forms of n-(3-(2-(2-hydroxyethoxy)-6-morpholinopyridin-4-yl)-4-methvlphenyl)-2(trifluoromethyl)isonicotinamide as raf inhibitors for the treatment of cancer
WO2021154156A1 (en) * 2020-01-31 2021-08-05 Agency For Science, Technology And Research Anti-axl antibody and uses thereof
BR112022015977A2 (pt) * 2020-02-28 2022-10-11 Symphogen As Anticorpos anti-axl e composições
WO2021229439A1 (en) * 2020-05-12 2021-11-18 Novartis Ag Therapeutic combinations comprising a craf inhibitor
WO2022026807A2 (en) * 2020-07-30 2022-02-03 Albert Einstein College Of Medicine Antibodies targeting sars-cov-2 and uses thereof
AU2021376286A1 (en) * 2020-11-06 2023-06-22 Dana-Farber Cancer Institute, Inc. Raf inhibitor for treating low grade glioma
MX2023008744A (es) 2021-01-29 2023-10-02 Illimis Therapeutics Inc Molecula de fusion que tiene actividad no inflamatoria inductora de la fagocitosis.
CN117177754A (zh) * 2021-02-19 2023-12-05 首日生物制药公司 Raf抑制剂和mek抑制剂的组合
WO2024178139A1 (en) * 2023-02-22 2024-08-29 Resolute Science, Inc. Compositions and methods for targeting tumor-associated macrophages
WO2024178140A1 (en) * 2023-02-22 2024-08-29 Resolute Science, Inc. Compositions and methods for targeting tumor-associated macrophages

Family Cites Families (102)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US761218A (en) 1899-10-05 1904-05-31 U S Standard Voting Machine Co Register or counter.
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
JPS5896026A (ja) 1981-10-30 1983-06-07 Nippon Chemiphar Co Ltd 新規ウロキナ−ゼ誘導体およびその製造法ならびにそれを含有する血栓溶解剤
US4609546A (en) 1982-06-24 1986-09-02 Japan Chemical Research Co., Ltd. Long-acting composition
US4681581A (en) 1983-12-05 1987-07-21 Coates Fredrica V Adjustable size diaper and folding method therefor
US4766106A (en) 1985-06-26 1988-08-23 Cetus Corporation Solubilization of proteins for pharmaceutical compositions using polymer conjugation
US5101827A (en) 1985-07-05 1992-04-07 Immunomedics, Inc. Lymphographic and organ imaging method and kit
US4735210A (en) 1985-07-05 1988-04-05 Immunomedics, Inc. Lymphographic and organ imaging method and kit
US5776093A (en) 1985-07-05 1998-07-07 Immunomedics, Inc. Method for imaging and treating organs and tissues
US5057313A (en) 1986-02-25 1991-10-15 The Center For Molecular Medicine And Immunology Diagnostic and therapeutic antibody conjugates
US5648471A (en) 1987-12-03 1997-07-15 Centocor, Inc. One vial method for labeling antibodies with Technetium-99m
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
JP3070763B2 (ja) 1989-08-09 2000-07-31 ロメッド インコーポレイティド テクネチウムまたはレニウムでの抗体または他のタンパク質の直接放射能標識
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
AU8507191A (en) 1990-08-29 1992-03-30 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US6300129B1 (en) 1990-08-29 2001-10-09 Genpharm International Transgenic non-human animals for producing heterologous antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5814318A (en) 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
US5877397A (en) 1990-08-29 1999-03-02 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5789650A (en) 1990-08-29 1998-08-04 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5874299A (en) 1990-08-29 1999-02-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5194594A (en) 1990-09-07 1993-03-16 Techniclone, Inc. Modified antibodies
WO1992022645A1 (en) 1991-06-14 1992-12-23 Genpharm International, Inc. Transgenic immunodeficient non-human animals
JPH06508880A (ja) 1991-07-08 1994-10-06 ユニバーシティ オブ マサチューセッツ アット アムハースト サーモトロピック液晶セグメント化ブロックコポリマー
US5635483A (en) 1992-12-03 1997-06-03 Arizona Board Of Regents Acting On Behalf Of Arizona State University Tumor inhibiting tetrapeptide bearing modified phenethyl amides
US5780588A (en) 1993-01-26 1998-07-14 Arizona Board Of Regents Elucidation and synthesis of selected pentapeptides
AU6819494A (en) 1993-04-26 1994-11-21 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US6214345B1 (en) 1993-05-14 2001-04-10 Bristol-Myers Squibb Co. Lysosomal enzyme-cleavable antitumor drug conjugates
US6077835A (en) 1994-03-23 2000-06-20 Case Western Reserve University Delivery of compacted nucleic acid to cells
US5663149A (en) 1994-12-13 1997-09-02 Arizona Board Of Regents Acting On Behalf Of Arizona State University Human cancer inhibitory pentapeptide heterocyclic and halophenyl amides
KR970029803A (ko) 1995-11-03 1997-06-26 김광호 반도체 메모리장치의 프리차지 회로
DK0979281T3 (da) 1997-05-02 2005-11-21 Genentech Inc Fremgangsmåde til fremstilling af multispecifikke antistoffer med heteromultimere og fælles bestanddele
CA2361421A1 (en) 1999-02-03 2000-08-10 Biosante Pharmaceuticals, Inc. Therapeutic calcium phosphate particles and methods of manufacture and use
US6281005B1 (en) 1999-05-14 2001-08-28 Copernicus Therapeutics, Inc. Automated nucleic acid compaction device
DE60037896D1 (de) 1999-07-29 2008-03-13 Medarex Inc Menschliche antikörper gegen her2/neu
DE10043437A1 (de) 2000-09-04 2002-03-28 Horst Lindhofer Verwendung von trifunktionellen bispezifischen und trispezifischen Antikörpern zur Behandlung von malignem Aszites
EP1243276A1 (en) 2001-03-23 2002-09-25 Franciscus Marinus Hendrikus De Groot Elongated and multiple spacers containing activatible prodrugs
US7087600B2 (en) 2001-05-31 2006-08-08 Medarex, Inc. Peptidyl prodrugs and linkers and stabilizers useful therefor
EP2314629B2 (en) 2002-07-18 2022-11-16 Merus N.V. Recombinant production of mixtures of antibodies
ES2544527T3 (es) 2002-07-31 2015-09-01 Seattle Genetics, Inc. Conjugados de fármacos y su uso para tratar el cáncer, una enfermedad autoinmune o una enfermedad infecciosa
US7705045B2 (en) 2002-11-14 2010-04-27 Syntarga, B.V. Prodrugs built as multiple self-elimination-release spacers
EP3434275A1 (en) 2003-11-06 2019-01-30 Seattle Genetics, Inc. Assay for cancer cells based on the use of auristatin conjugates with antibodies
US7741568B2 (en) 2005-01-13 2010-06-22 The Wiremold Company Downward facing receptacle assembly for cable raceway
CN101198698B (zh) 2005-03-31 2014-03-19 中外制药株式会社 通过调节多肽缔合制备多肽的方法
US8158590B2 (en) 2005-08-05 2012-04-17 Syntarga B.V. Triazole-containing releasable linkers, conjugates thereof, and methods of preparation
US7612181B2 (en) 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
US10155816B2 (en) 2005-11-28 2018-12-18 Genmab A/S Recombinant monovalent antibodies and methods for production thereof
US8940784B2 (en) 2006-02-02 2015-01-27 Syntarga B.V. Water-soluble CC-1065 analogs and their conjugates
CN103073639A (zh) 2006-03-17 2013-05-01 比奥根艾迪克Ma公司 稳定的多肽组合物
WO2007110205A2 (en) 2006-03-24 2007-10-04 Merck Patent Gmbh Engineered heterodimeric protein domains
AT503902B1 (de) 2006-07-05 2008-06-15 F Star Biotech Forsch & Entw Verfahren zur manipulation von immunglobulinen
EP2070956A1 (en) 2007-12-14 2009-06-17 Total Petrochemicals Research Feluy Process for the production of a bimodal polypropylene having low ash content
CA2691434C (en) 2007-06-21 2020-07-21 Macrogenics, Inc. Covalent diabodies and uses thereof
ES2433379T3 (es) 2007-08-01 2013-12-10 Syntarga B.V. Análogos de CC-1065 sustituidos y sus conjugados
EP2050764A1 (en) 2007-10-15 2009-04-22 sanofi-aventis Novel polyvalent bispecific antibody format and uses thereof
CA2705164A1 (en) 2007-11-12 2009-05-22 U3 Pharma Gmbh Axl antibodies
KR101568051B1 (ko) 2007-11-15 2015-11-10 추가이 세이야쿠 가부시키가이샤 Anexelekto에 결합하는 단일클론항체, 및 그의 이용
US8227577B2 (en) 2007-12-21 2012-07-24 Hoffman-La Roche Inc. Bivalent, bispecific antibodies
US8242247B2 (en) 2007-12-21 2012-08-14 Hoffmann-La Roche Inc. Bivalent, bispecific antibodies
US9266967B2 (en) 2007-12-21 2016-02-23 Hoffmann-La Roche, Inc. Bivalent, bispecific antibodies
US20090162359A1 (en) 2007-12-21 2009-06-25 Christian Klein Bivalent, bispecific antibodies
EP3663318A1 (en) 2008-01-07 2020-06-10 Amgen Inc. Method for making antibody fc-heterodimeric molecules using electrostatic steering effects
WO2010015792A1 (en) 2008-08-06 2010-02-11 Argenta Discovery Limited Nitrogen containing heterocyclic compounds useful as bifunctional modulators of m3 receptors and beta-2 receptors
JP5397668B2 (ja) 2008-09-02 2014-01-22 ソニー株式会社 記憶素子および記憶装置
MX2011004625A (es) 2008-11-03 2011-07-20 Syntarga Bv Analogos cc-1065 novedosos y sus conjugados.
ES2733067T3 (es) 2008-12-19 2019-11-27 Macrogenics Inc Diacuerpos covalentes y usos de los mismos
AU2010245011B2 (en) 2009-04-27 2015-09-03 Oncomed Pharmaceuticals, Inc. Method for making heteromultimeric molecules
JP5909442B2 (ja) 2009-05-11 2016-04-26 ユー3・ファーマ・ゲーエムベーハー ヒト化axl抗体
RU2011151069A (ru) 2009-05-15 2013-06-20 Чугаи Сейяку Кабусики Кайся Анти-axl антитело
LT2975051T (lt) 2009-06-26 2021-07-12 Regeneron Pharmaceuticals, Inc. Lengvai išskiriami bispecifiniai antikūnai su natyvios formos imunoglobulinu
LT2769737T (lt) * 2009-07-20 2017-06-26 Bristol-Myers Squibb Company Anti-ctla4 antikūno derinys su etopozidu, skirtas sinerginiam proliferacinių ligų gydymui
WO2011028952A1 (en) 2009-09-02 2011-03-10 Xencor, Inc. Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens
WO2011113942A2 (en) * 2010-03-18 2011-09-22 Institut National De La Sante Et De La Recherche Medicale (Inserm) Method for predicting the responsiveness to chemotherapy
AR080794A1 (es) 2010-03-26 2012-05-09 Hoffmann La Roche Anticuerpos bivalentes biespecificos anti- vegf/ anti-ang-2
JP6040148B2 (ja) 2010-04-20 2016-12-07 ゲンマブ エー/エス ヘテロ二量体抗体Fc含有タンパク質およびその産生方法
EP2569337A1 (en) 2010-05-14 2013-03-20 Rinat Neuroscience Corp. Heterodimeric proteins and methods for producing and purifying them
CA2794731C (en) 2010-06-18 2019-03-19 Genentech, Inc. Anti-axl antibodies and methods of use
AU2011290480B2 (en) 2010-08-16 2015-07-30 Novimmune S.A. Methods for the generation of multispecific and multivalent antibodies
RU2013110876A (ru) 2010-08-24 2014-09-27 Рош Гликарт Аг Активируемые биспецифические антитела
RU2013110875A (ru) 2010-08-24 2014-09-27 Ф.Хоффманн-Ля Рош Аг БИСПЕЦИФИЧЕСКИЕ АНТИТЕЛА, СОДЕРЖАЩИЕ СТАБИЛИЗИРОВАННЫЙ ДИСУЛЬФИДОМ ФРАГМЕНТ Fv
PL2635607T3 (pl) 2010-11-05 2020-05-18 Zymeworks Inc. Projekt stabilnego przeciwciała heterodimerowego z mutacjami w domenie FC
CN102250246A (zh) 2011-06-10 2011-11-23 常州亚当生物技术有限公司 抗VEGF/PDGFRβ双特异性抗体及其应用
JP6033293B2 (ja) 2011-06-22 2016-11-30 インサーム(インスティテュ ナシオナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシェ メディカル)Inserm(Institut National Dela Sante Et De La Recherche Medicale) 抗Axl抗体及びその使用
US9409988B2 (en) 2011-06-22 2016-08-09 Inserm (Institut National De La Sante Et De La Recherche Medicale) Anti-Axl antibodies and uses thereof
EP2589609A1 (en) 2011-11-03 2013-05-08 Pierre Fabre Medicament Antigen binding protein and its use as addressing product for the treatment of cancer
US9879061B2 (en) 2011-12-15 2018-01-30 The Board Of Trustees Of The Leland Stanford Junior University Inhibition of AXL/GAS6 signaling in the treatment of liver fibrosis
PT2794905T (pt) 2011-12-20 2020-06-30 Medimmune Llc Polipéptidos modificados para estrutura de anticorpos bispecíficos
DK2838918T3 (da) 2012-04-20 2019-08-12 Merus Nv Fremgangsmåder og midler til fremstilling af heterodimere ig-lignende molekyler
EP3925627A1 (en) 2012-05-15 2021-12-22 Concortis Biosystems, Corp Drug-conjugates and uses thereof
CA2890265C (en) * 2012-11-05 2023-01-17 Pierre Fabre Medicament Antigen binding proteins and their use as addressing product for the treatment of cancer
WO2014093707A1 (en) 2012-12-14 2014-06-19 The Board Of Trustees Of The Leland Stanford Junior University Inhibition of axl signaling in primary tumor therapy
US20160097370A1 (en) * 2013-03-26 2016-04-07 James L. Rodgers High-torque wind turbine
US20160106861A1 (en) * 2013-04-26 2016-04-21 Spirogen Sarl Axl antibody-drug conjugate and its use for the treatment of cancer
US10028958B2 (en) * 2014-04-19 2018-07-24 Massachusetts Institute Of Technology Methods of treating cancer with a combination of selected MEK1/2 and AXL inhibitors
GB201410825D0 (en) * 2014-06-18 2014-07-30 Bergenbio As Anti-axl antibodies
EP3169706B1 (en) * 2014-07-11 2019-12-04 Genmab A/S Antibodies binding axl
CA2991805A1 (en) * 2015-07-10 2017-01-19 Genmab A/S Axl-specific antibody-drug conjugates for cancer treatment
MA45625A (fr) * 2016-07-08 2019-05-15 Genmab As Nouveaux régimes posologiques pour conjugués anticorps-médicaments à base d'anticorps anti-axl

Similar Documents

Publication Publication Date Title
KR102905497B1 (ko) 항체-약물 컨쥬게이트와 parp 저해제의 조합
JP2024161445A (ja) 抗体-薬物コンジュゲートとキナーゼ阻害剤の組み合わせ
JP2020525542A5 (enExample)
HRP20200551T1 (hr) Axl-specifični konjugati protutijelo-lijek za liječenje raka
CN110248963B (zh) 抗ccr7抗体药物缀合物
JP2024075668A (ja) 抗体-薬物コンジュゲートとチューブリン阻害剤の組み合わせ
JP6581279B2 (ja) 抗folr1免疫抱合体投薬レジメン
JPWO2020130125A5 (enExample)
US9233171B2 (en) Method of treatment of tumors that are resistant to EGFR antibody therapies by EGFR antibody cytotoxic agent conjugate
JP2017522871A5 (enExample)
CN115969970A (zh) Abcg2抑制剂与sacituzumab govitecan的组合
JP2021521143A5 (enExample)
HRP20200283T1 (hr) Protutijela koja se vežu na axl
AU2017234163A1 (en) NaPi2b-targeted antibody-drug conjugates and methods of use thereof
JP2019509257A5 (enExample)
JP2018524295A (ja) 抗体及び免疫複合体
JP2019524713A5 (enExample)
CN116390772A (zh) 新型美登素类似物作为adc有效载荷及其在癌症治疗中的用途
CN118994402A (zh) 针对pmel17的抗体及其缀合物
JP2026501556A (ja) 抗体薬物複合体
KR20190068550A (ko) 항-c met 항체-세포독성 약물 컨쥬게이트의 의학적 용도
TW202541808A (zh) 抗癌組合治療
WO2024219442A1 (ja) 抗体-薬物コンジュゲートと他の薬剤との組み合わせ
WO2024050031A2 (en) Novel camptothecin derivatves as antibody-drug conjugates (adc) payloads
CN116096426A (zh) 用于治疗癌症的ccr7抗体药物缀合物